High materiality7/10
Avalyn Pharma initiated with an Outperform at Raymond James
Why it may matterVerify against the original reporting
Outperform initiation supports bullish view.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Raymond James initiates AVLN with Outperform; target $60 vs current price $27.42; priceChangeSinceSignal +2.59.
- Raymond James initiates AVLN with Outperform
- Target $60 vs current $27.42
- Price change since signal +2.59
Key facts
- 01
Target: $60
- 02
Posted price: $27.42
- 03
Analyst firm: Raymond James
- 04
Analyst: Tiago Fauth
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.